The effect of CYP2C19 polymorphism on the safety,tolerability, and pharmacokinetics of tivantinib (ARQ 197): Results from a phase I trial in advanced solid tumors

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1653-1659

  Yamamoto, N ^a   Muraakmi, H ^a   Nishina, T ^b   Hirashima, T ^c   Sugio, K ^d   Muro, K ^e   Takahashi, T ^a   Naito, T ^a   Yasui, H ^a   Akinaga, S ^f   Koh, Y ^a   Boku, N ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^c OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

c Met inhibitor; CYP2C19 polymorphism; Pharmacokinetics; Phase I study; Tivantinib

Indexed keywords

CYTOCHROME P450 2C19; GRANULOCYTE COLONY STIMULATING FACTOR; TIVANTINIB;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CYP2C19 GENE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LEUKOPENIA; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; ONCOGENE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SINUS BRADYCARDIA; SOLID TUMOR;

C-MET INHIBITOR; CYP2C19 POLYMORPHISM; PHARMACOKINETICS; PHASE I STUDY; TIVANTINIB;

ARYL HYDROCARBON HYDROXYLASES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, GENETIC; PYRROLIDINONES; QUINOLINES; TREATMENT OUTCOME;

EID: 84878441820     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt014     Document Type: Article

References (27)

1. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: Targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504-516.
2. Yap TA, de Bono JS. Targeting the HGF/c-Met axis: state of play. Mol Cancer Ther 2010; 9: 1077-1079.
3. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 2010; 46: 1260-1270.
4. Eder JP, Woude GFV, Boerner SA et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009; 15: 2207-2214.
5. Sattler M, Hasina R, Reddy MM et al. The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 2011; 3: 171-184.
6. Munshi N, Jeay S, Li Y et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010; 9: 1544-1553.
7. Eathiraj S, Palma R, Volckova E et al. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymalepithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 2011; 286: 20666-20676.
8. Sequist LV, von Pawel J, Garmey EG et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011; 29: 3307-3315.
9. Bessudo A, Bendell JC, Gabrail N et al. Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients ( pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy. J Clin Oncol 2011; 29: 3582 (abstract).
10. Borbath I, Santoro A, Van Laethem J et al. ARQ 197-215: A randomized, placebo-controlled phase II clinical trial evaluating the c-Met inhibitor, ARQ 197, in patients ( pts) with hepatocellular carcinoma (HCC). J Clin Oncol 2010; 28 (15s): TPS215 (abstract).
11. Feldman DR, Einhorn LH, Quinn DI et al. A phase II multicenter evaluation of ARQ 197 monotherapy in patients with relapsed or refractory germ cell tumors (GCTs). J Clin Oncol 2011; 29: 4638 (abstract).
12. Yap TA, Olmos D, Brunetto AT et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011; 29: 1271-1279.
13. Rosen LS, Senzer N, Mekhail T et al. A phase I dose escalation study of tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 2011; 17: 7754-7764.
14. Adjei AA, Schwartz B, Garmey E. Early Clinical development of ARQ 197, a selective, non-ATP competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist 2011; 16: 788-799.
15. Scordo MG, Pengo V, Spina E et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702-710.
16. Sim SC, Risinger C, Dahl M et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006; 79: 103-113.
17. Kubota T, Chiba K, Iga T. Frequency distribution of CYP2C19, CYP2D6, and CYP2C9 mutant-alleles in several different populations. Xenobio Metab Dispos 2001; 16: 69-74.
18. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc. htm
19. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
20. Mor V, Laliberte L, Morris JN et al. The Karnofsky performance status scale: an examination of its reliability and validity in a research setting. Cancer 1984; 53: 2002-2007.
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
22. Melton L. Protein arrays: Proteomics in multiplex. Nature 2004; 429: 101-107.
23. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Pharmacol Toxicol 2004; 95: 2-8.
24. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006; 44: 297-302.
25. Helsby NA, Lo WY, Sharples K et al. CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype. Br J Cancer 2008; 99: 1251-1255.
26. Kasahara K, Arao T, Sakai K et al. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Clin Cancer Res 2010; 16: 4616-4624.
27. Yano S, Yamada T, Takeuchi S et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011; 6: 2011-2017.